Comparison of monitoring methods for lepirudin: Impact of warfarin and lupus anticoagulant

Thrombosis Research

Volumn 125, Issue 6, 2010, Pages 538-544

  Salmela, Birgitta ^a   Joutsi Korhonen, Lotta ^b   Saarela, Ellen ^b   Lassila, Riitta ^a,b  

^a Department of Internal Medicine ^*  (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Direct thrombin inhibitor; Ecarin; Hirudin; Lupus anticoagulant; Oral anticoagulant

Indexed keywords

BLOOD CLOTTING FACTOR 10A; ECARIN; LEPIRUDIN; LUPUS ANTICOAGULANT; PROTHROMBIN ANTIBODY; WARFARIN; CHROMOGENIC SUBSTRATE; FIBRINOLYTIC AGENT; FIIA; HIRUDIN DERIVATIVE; METALLOPROTEINASE; PROTEINASE; RECOMBINANT PROTEIN; SNAKE VENOM;

ADULT; AGED; ANTICOAGULATION; AORTA THROMBOSIS; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; DRUG MONITORING; HUMAN; HUMAN CELL; INTERNATIONAL NORMALIZED RATIO; LEG ISCHEMIA; LIVER VEIN THROMBOSIS; LUNG EMBOLISM; PARTIAL THROMBOPLASTIN TIME; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; THROMBIN TIME; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; DIAGNOSTIC USE; EVALUATION STUDY; PROCEDURES;

CHROMOGENIC COMPOUNDS; CROTALID VENOMS; DRUG MONITORING; ENDOPEPTIDASES; FIBRINOLYTIC AGENTS; HIRUDINS; HUMANS; LUPUS COAGULATION INHIBITOR; PARTIAL THROMBOPLASTIN TIME; RECOMBINANT PROTEINS; WARFARIN; METALLOENDOPEPTIDASES;

EID: 77952552934     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2010.02.002     Document Type: Article

References (36)

1. Harvey R.P., Degryse E., Stefani L., Schamber F., Cazenave J.P., Courtney M., et al. Cloning and expression of a cDNA coding for the anticoagulant hirudin from the bloodsucking leech, Hirudo medicinalis. Proc Natl Acad Sci U S A 83 (1986) 1084-1088
2. Fenton II J.W., Villanueva G.B., Ofosu F.A., and Maraganore J.M. Thrombin inhibition by hirudin: how hirudin inhibits thrombin. Haemostasis 21 (1991) 27-31
3. Agnelli G., Renga C., Weitz J.I., Nenci G.G., and Hirsh J. Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin. Blood 80 (1992) 960-965
4. Warkentin T.E., Greinacher A., Koster A., Lincoff A.M., and American College of Chest P. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 (2008) 340S-380S
5. Fischer K.G. The role of recombinant hirudins in the management of thrombotic disorders. BioDrugs 18 (2004) 235-268
6. Di Nisio M., Middeldorp S., and Buller H.R. Direct thrombin inhibitors. N Engl J Med 353 (2005) 1028-1040
7. Greinacher A., and Warkentin T.E. The direct thrombin inhibitor hirudin. Thromb Haemost 99 (2008) 819-829
8. Kuitunen A., Suojaranta-Ylinen R., Raivio P., Kukkonen S., and Lassila R. Heparin-induced thrombocytopenia following cardiac surgery is associated with poor outcome. J Cardiothorac Vasc Anesth 21 (2007) 18-22
9. Salmela B., Nordin A., Vuoristo M., Mäkisalo H., Numminen K., and Lassila R. Budd-Chiari syndrome in a young female with factor V Leiden mutation: successful treatment with lepirudin, a direct thrombin inhibitor. Thromb Res 121 (2008) 769-772
10. Salmela B., Albäck A., Räike P., Lepäntalo M., and Lassila R. A direct thrombin inhibitor, lepirudin, for thrombophilic patients with inoperable critical limb ischemia. Thromb Res 123 (2009) 719-723
11. Gray E., Harenberg J., and ISTH Control of Anticoagulation SSC Working Group on Thrombin Inhibitors. Collaborative study on monitoring methods to determine direct thrombin inhibitors lepirudin and argatroban. J Thromb Haemost 3 (2005) 2096-2097
12. Nowak G. Clinical monitoring of hirudin and direct thrombin inhibitors. Semin Thromb Hemost 27 (2001) 537-541
13. Fenyvesi T., Jorg I., and Harenberg J. Monitoring of anticoagulant effects of direct thrombin inhibitors. Semin Thromb Hemost 28 (2002) 361-368
14. Gosselin R.C., Dager W.E., King J.H., Janatpour K., Mahackian K., Larkin E.C., et al. Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values. Am J Clin Pathol 121 (2004) 593-599
15. Nowak G., and Bucha E. Quantitative determination of hirudin in blood and body fluids. Semin Thromb Hemost 22 (1996) 197-202
16. Lange U., Nowak G., and Bucha E. Ecarin chromogenic assay-a new method for quantitative determination of direct thrombin inhibitors like hirudin. Pathophysiol Haemost Thromb 33 (2003) 184-191
17. Calatzis A., Peetz D., Haas S., Spannagl M., Rudin K., and Wilmer M. Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors. Am J Clin Pathol 130 (2008) 446-454
18. Hafner G., Fickenscher K., Friesen H.J., Rupprecht H.J., Konheiser U., Ehrenthal W., et al. Evaluation of an automated chromogenic substrate assay for the rapid determination of hirudin in plasma. Thromb Res 77 (1995) 165-173
19. Love J.E., Ferrell C., and Chandler W.L. Monitoring direct thrombin inhibitors with a plasma diluted thrombin time. Thromb Haemost 98 (2007) 234-242
20. Guy S., Kitchen S., Laidlaw S., Cooper P., Woolley A., and Maclean R. The use of ecarin chromogenic assay and prothrombinase induced clotting time in the monitoring of lepirudin for the treatment of heparin-induced thrombocytopenia. Br J Haematol 142 (2008) 466-468
21. Warkentin T.E., and Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 311S-337S
22. Lange U., Olschewski A., Nowak G., and Bucha E. Ecarin chromogenic assay: an innovative test for quantitative determination of direct thrombin inhibitors in plasma. Hamostaseologie 25 (2005) 293-300
23. Fenyvesi T., Jorg I., Weiss C., and Harenberg J. Effects of vitamin K antagonist phenprocoumon on activated partial thromboplastin time measurement of direct thrombin inhibitors. Blood Coagul Fibrinolysis 15 (2004) 605-611
24. Fenyvesi T., Jorg I., and Harenberg J. Effect of phenprocoumon on monitoring of lepirudin, argatroban, melagatran and unfractionated heparin with the PiCT method. Pathophysiol Haemost Thromb 32 (2002) 174-179
25. Bates S.M., and Weitz J.I. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. Am J Cardiol 82 (1998) 12P-18P
26. Weitz J.I., Leslie B., and Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation 97 (1998) 544-552
27. Kelly A.B., Marzec U.M., Krupski W., Bass A., Cadroy Y., Hanson S.R., et al. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons. Blood 77 (1991) 1006-1012
28. Vanholder R.C., Camez A.A., Veys N.M., Soria J., Mirshahi M., Soria C., et al. Recombinant hirudin: a specific thrombin inhibiting anticoagulant for hemodialysis. Kidney Int 45 (1994) 1754-1759
29. Fischer K.G. Hirudin in renal insufficiency. Semin Thromb Hemost 28 (2002) 467-482
30. Tardy B., Lecompte T., Boelhen F., Tardy-Poncet B., Elalamy I., Morange P., et al. Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood 108 (2006) 1492-1496
31. Tardy-Poncet B., Charier D., Diconne E., Zeni F., Garraud O., Tardy B., et al. Extremely low doses of lepirudin in a patient with heparin-induced thrombocytopenia, high bleeding risk and renal insufficiency. Br J Haematol 146 (2009) 456-457
32. Tschudi M., Lammle B., and Alberio L. Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients. Blood 113 (2009) 2402-2409
33. Mueck W., Borris L.C., Dahl O.E., Haas S., Huisman M.V., Kakkar A.K., et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 100 (2008) 453-461
34. Eikelboom J.E., and Weitz J.I. Dabigatran etexilate for prevention of venous thromboembolism. Thromb Haemost 101 (2009) 2-4
35. Harder S., Graff J., Klinkhardt U., von Hentig N., Walenga J.M., Watanabe H., et al. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and ecarin clotting time. Thromb Haemost 91 (2004) 1137-1145
36. Nowak G., Lange U., and Bucha E. Drug monitoring of argatroban using the ecarin chromogenic assay. Semin Thromb Haemost 34 S1 (2008) 81-86